New Orleans startup Chosen Diagnostics is focused on delivering better outcomes for the most fragile patient population by combining scientific expertise with leading-edge technologies.
Chosen Diagnostics has received a Small Business Innovation Research Program (SBIR) Phase I grant from the National Science Foundation (NSF) totaling $224,758.
The grant will go towards the development and commercialization of the company’s biomarker for noninvasive detection of necrotizing enterocolitis.
“This substantial SBIR grant from NSF, coupled with the award from NIH, afford us the ability to really make headway further developing the biomarker test and eventually bringing it to market,” said Dr. Rebecca Buckley, the company’s COO.
For more information, visit ChosenDiagnostics.com.